Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling

Science Signaling

Volumn 4, Issue 166, 2011, Pages

  Rubbi, Liudmilla ^a   Titz, Björn ^a   Brown, Lauren ^a   Galvan, Erica ^a   Komisopoulou, Evangelia ^a   Chen, Sharon S ^a   Low, Tracey ^a   Tahmasian, Martik ^a   Skaggs, Brian ^a   Müschen, Markus ^b   Pellegrini, Matteo ^c   Graeber, Thomas G ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BCR ABL PROTEIN; C TERMINAL SRC KINASE CSK BINDING PROTEIN PAG1; DASATINIB; HEMATOPOIETIC CELL KINASE; IMATINIB; PHOSPHOPEPTIDE; PROTEIN CSK; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; TYROSINE PHOSPHATASE PTPN18; UNCLASSIFIED DRUG; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; CSK PROTEIN, HUMAN; MEMBRANE PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; ONCOPROTEIN; PAG1 PROTEIN, HUMAN; PTPN18 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL TRANSFORMATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FUNCTIONAL PROTEOMICS; HUMAN; LEUKEMIA; MASS SPECTROMETRY; MOLECULAR INTERACTION; NEGATIVE FEEDBACK; NONHUMAN; PHOSPHOPROTEOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; CELL LINE; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; PROTEIN-TYROSINE KINASES; PROTEOMICS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 79953250081     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2001314     Document Type: Article

References (76)

1. Y. Hu, Y. Liu, S. Pelletier, E. Buchdunger, M. Warmuth, D. Fabbro, M. Hallek, R. A. Van Etten, S. Li, Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat. Genet. 36, 453-461 (2004).
2. + leukemia in mice. Proc. Natl. Acad. Sci. U.S.A. 103, 16870-16875 (2006).
3. M. Talpaz, N. P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O'Brien, C. Nicaise, E. Bleickardt, M. A. Blackwood-Chirchir, V. Iyer, T. T. Chen, F. Huang, A. P. Decillis, C. L. Sawyers, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531-2541 (2006).
4. F. Guilhot, J. Apperley, D. W. Kim, E. O. Bullorsky, M. Baccarani, G. J. Roboz, S. Amadori, C. A. de Souza, J. H. Lipton, A. Hochhaus, D. Heim, R. A. Larson, S. Branford, M. C. Muller, P. Agarwal, A. Gollerkeri, M. Talpaz, Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109, 4143-4150 (2007).
5. T. A. Carter, L. M. Wodicka, N. P. Shah, A. M. Velasco, M. A. Fabian, D. K. Treiber, Z. V. Milanov, C. E. Atteridge, W. H. Biggs III, P. T. Edeen, M. Floyd, J. M. Ford, R. M. Grotzfeld, S. Herrgard, D. E. Insko, S. A. Mehta, H. K. Patel, W. Pao, C. L. Sawyers, H. Varmus, P. P. Zarrinkar, D. J. Lockhart, Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U.S.A. 102, 11011-11016 (2005).
6. M. W. Karaman, S. Herrgard, D. K. Treiber, P. Gallant, C. E. Atteridge, B. T. Campbell, K. W. Chan, P. Ciceri, M. I. Davis, P. T. Edeen, R. Faraoni, M. Floyd, J. P. Hunt, D. J. Lockhart, Z. V. Milanov, M. J. Morrison, G. Pallares, H. K. Patel, S. Pritchard, L. M. Wodicka, P. P. Zarrinkar, A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
7. B. J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, N. B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
8. M. A. Fabian, W. H. Biggs III, D. K. Treiber, C. E. Atteridge, M. D. Azimioara, M. G. Benedetti, T. A. Carter, P. Ciceri, P. T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J. L. Gerlach, R. M. Grotzfeld, S. Herrgard, D. E. Insko, M. A. Insko, A. G. Lai, J. M. Lelias, S. A. Mehta, Z. V. Milanov, A. M. Velasco, L. M. Wodicka, H. K. Patel, P. P. Zarrinkar, D. J. Lockhart, A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
9. Y. Dai, M. Rahmani, S. J. Corey, P. Dent, S. Grant, A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. 279, 34227-34239 (2004).
10. N. J. Donato, J. Y. Wu, J. Stapley, G. Gallick, H. Lin, R. Arlinghaus, M. Talpaz, BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690-698 (2003).
11. T. Ito, H. Tanaka, A. Kimura, Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur. J. Haematol. 78, 417-431 (2007).
12. P. Ramirez, J. F. DiPersio, Therapy options in imatinib failures. Oncologist 13, 424-434 (2008).
13. J. Wu, F. Meng, L. Y. Kong, Z. Peng, Y. Ying, W. G. Bornmann, B. G. Darnay, B. Lamothe, H. Sun, M. Talpaz, N. J. Donato, Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J. Natl. Cancer Inst. 100, 926-939 (2008).
14. A. Ptasznik, Y. Nakata, A. Kalota, S. G. Emerson, A. M. Gewirtz, Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. 10, 1187-1189 (2004).
15. E. Ingley, Src family kinases: Regulation of their activities, levels and identification of new pathways. Biochim. Biophys. Acta 1784, 56-65 (2008).
16. S. M. Thomas, J. S. Brugge, Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13, 513-609 (1997).
17. M. Kawabuchi, Y. Satomi, T. Takao, Y. Shimonishi, S. Nada, K. Nagai, A. Tarakhovsky, M. Okada, Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 404, 999-1003 (2000).
18. C. Oneyama, T. Hikita, K. Enya, M. W. Dobenecker, K. Saito, S. Nada, A. Tarakhovsky, M. Okada, The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol. Cell 30, 426-436 (2008).
19. S. Q. Zhang, W. Yang, M. I. Kontaridis, T. G. Bivona, G. Wen, T. Araki, J. Luo, J. A. Thompson, B. L. Schraven, M. R. Philips, B. G. Neel, Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 13, 341-355 (2004).
20. T. Brdicka, D. Pavlistová, A. Leo, E. Bruyns, V. Korinek, P. Angelisová, J. Scherer, A. Shevchenko, I. Hilgert, J. Cerný, K. Drbal, Y. Kuramitsu, B. Kornacker, V. Horejsí, B. Schraven, Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J. Exp. Med. 191, 1591-1604 (2000).
21. T. Shima, S. Nada, M. Okada, Transmembrane phosphoprotein Cbp senses cell adhesion signaling mediated by Src family kinase in lipid rafts. Proc. Natl. Acad. Sci. U.S.A. 100, 14897-14902 (2003).
22. L. A. Cary, J. A. Cooper, Molecular switches in lipid rafts. Nature 404, 945, 947 (2000).
23. B. Wang, S. Lemay, S. Tsai, A. Veillette, SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with protein tyrosine phosphatase-HSCF. Mol. Cell. Biol. 21, 1077-1088 (2001).
24. B. J. Skaggs, M. E. Gorre, A. Ryvkin, M. R. Burgess, Y. Xie, Y. Han, E. Komisopoulou, L. M. Brown, J. A. Loo, E. M. Landaw, C. L. Sawyers, T. G. Graeber, Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc. Natl. Acad. Sci. U.S.A. 103, 19466-19471 (2006).
25. J. Rush, A. Moritz, K. A. Lee, A. Guo, V. L. Goss, E. J. Spek, H. Zhang, X. M. Zha, R. D. Polakiewicz, M. J. Comb, Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23, 94-101 (2005).
26. A. Zimman, S. S. Chen, E. Komisopoulou, B. Titz, R. Martínez- Pinna, A. Kafi, J. A. Berliner, T. G. Graeber, Activation of aortic endothelial cells by oxidized phospholipids: A phosphoproteomic analysis. J. Proteome Res. 9, 2812-2824 (2010).
27. N. P. Shah, C. Tran, F. Y. Lee, P. Chen, D. Norris, C. L. Sawyers, Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).
28. M. R. Burgess, B. J. Skaggs, N. P. Shah, F. Y. Lee, C. L. Sawyers, Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. U.S.A. 102, 3395-3400 (2005).
29. bcr/abl protein. Proc. Natl. Acad. Sci. U.S.A. 85, 9312-9316 (1988).
30. S. Li, R. L. Ilaria Jr., R. P. Million, G. Q. Daley, R. A. Van Etten, The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189, 1399-1412 (1999).
31. T. G. Graeber, J. R. Heath, B. J. Skaggs, M. E. Phelps, F. Remacle, R. D. Levine, Maximal entropy inference of oncogenicity from phosphorylation signaling. Proc. Natl. Acad. Sci. U.S.A. 107, 6112-6117 (2010).
32. J. Y. J. Wang, Antibodies for phosphotyrosine: Analytical and preparative tool for tyrosylphosphorylated proteins. Anal. Biochem. 172, 1-7 (1988).
33. T. S. Keshava Prasad, R. Goel, K. Kandasamy, S. Keerthikumar, S. Kumar, S. Mathivanan, D. Telikicherla, R. Raju, B. Shafreen, A. Venugopal, L. Balakrishnan, A. Marimuthu, S. Banerjee, D. S. Somanathan, A. Sebastian, S. Rani, S. Ray, C. J. Harrys Kishore, S. Kanth, M. Ahmed, M. K. Kashyap, R. Mohmood, Y. L. Ramachandra, V. Krishna, B. A. Rahiman, S. Mohan, P. Ranganathan, S. Ramabadran, R. Chaerkady, A. Pandey, Human Protein Reference Database - 2009 update. Nucleic Acids Res. 37, D767-D772 (2009).
34. J. C. Obenauer, L. C. Cantley, M. B. Yaffe, Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 31, 3635-3641 (2003).
35. S. Hunter, R. Apweiler, T. K. Attwood, A. Bairoch, A. Bateman, D. Binns, P. Bork, U. Das, L. Daugherty, L. Duquenne, R. D. Finn, J. Gough, D. Haft, N. Hulo, D. Kahn, E. Kelly, A. Laugraud, I. Letunic, D. Lonsdale, R. Lopez, M. Madera, J. Maslen, C. McAnulla, J. McDowall, J. Mistry, A. Mitchell, N. Mulder, D. Natale, C. Orengo, A. F. Quinn, J. D. Selengut, C. J. Sigrist, M. Thimma, P. D. Thomas, F. Valentin, D. Wilson, C. H. Wu, C. Yeats, InterPro: The integrative protein signature database. Nucleic Acids Res. 37, D211-D215 (2009).
36. Z. Songyang, K. L. Carraway III, M. J. Eck, S. C. Harrison, R. A. Feldman, M. Mohammadi, J. Schlessinger, S. R. Hubbard, D. P. Smith, C. Eng, M. J. Lorenzo, B. A. J. Ponder, B. J. Mayer, L. C. Cantley, Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373, 536-539 (1995).
37. M. D. Schaller, Paxillin: A focal adhesion-associated adaptor protein. Oncogene 20, 6459-6472 (2001).
38. P. Van Slyke, M. L. Coll, Z. Master, H. Kim, J. Filmus, D. J. Dumont, Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk. Mol. Cell. Biol. 25, 3831-3841 (2005).
39. K. Neet, T. Hunter, The nonreceptor protein-tyrosine kinase CSK complexes directly with the GTPase-activating protein-associated p62 protein in cells expressing v-Src or activated c-Src. Mol. Cell. Biol. 15, 4908-4920 (1995).
40. bcr/abl in myeloid cells. Cancer Res. 56, 3589-3596 (1996).
41. W. Lu, D. Gong, D. Bar-Sagi, P. A. Cole, Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol. Cell 8, 759-769 (2001).
42. J. Chen, W. M. Yu, H. Daino, H. E. Broxmeyer, B. J. Druker, C. K. Qu, SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 109, 778-785 (2007).
43. M. Dance, A. Montagner, J. P. Salles, A. Yart, P. Raynal, The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell. Signal. 20, 453-459 (2008).
44. B. W. Howell, J. A. Cooper, Csk suppression of Src involves movement of Csk to sites of Src activity. Mol. Cell. Biol. 14, 5402-5411 (1994).
45. G. Superti-Furga, S. Fumagalli, M. Koegl, S. A. Courtneidge, G. Draetta, Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J. 12, 2625-2634 (1993).
46. M. T. Brown, J. A. Cooper, Regulation, substrates and functions of Src. Biochim. Biophys. Acta 1287, 121-149 (1996).
47. W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. Rocha, J. Wu, F. Giles, P. W. Manley, P. Atadja, K. Bhalla, Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108, 645-652 (2006).
48. M. Thai, P. Y. Ting, J. McLaughlin, D. Cheng, M. Müschen, O. N. Witte, J. Colicelli, ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia 25, 290-300 (2011).
49. P. H. Huang, F. M. White, Phosphoproteomics: Unraveling the signaling web. Mol. Cell 31, 777-781 (2008).
50. K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, J. Nardone, K. Lee, C. Reeves, Y. Li, Y. Hu, Z. Tan, M. Stokes, L. Sullivan, J. Mitchell, R. Wetzel, J. Macneill, J. M. Ren, J. Yuan, C. E. Bakalarski, J. Villen, J. M. Kornhauser, B. Smith, D. Li, X. Zhou, S. P. Gygi, T. L. Gu, R. D. Polakiewicz, J. Rush, M. J. Comb, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
51. P. Filippakopoulos, M. Kofler, O. Hantschel, G. D. Gish, F. Grebien, E. Salah, P. Neudecker, L. E. Kay, B. E. Turk, G. Superti-Furga, T. Pawson, S. Knapp, Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134, 793-803 (2008).
52. R. Linding, L. J. Jensen, G. J. Ostheimer, M. A. van Vugt, C. Jorgensen, I. M. Miron, F. Diella, K. Colwill, L. Taylor, K. Elder, P. Metalnikov, V. Nguyen, A. Pasculescu, J. Jin, J. G. Park, L. D. Samson, J. R. Woodgett, R. B. Russell, P. Bork, M. B. Yaffe, T. Pawson, Systematic discovery of in vivo phosphorylation networks. Cell 129, 1415-1426 (2007).
53. A. Sirvent, C. Bénistant, J. Pannequin, L. Veracini, V. Simon, J. F. Bourgaux, F. Hollande, F. Cruzalegui, S. Roche, Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization. Oncogene 29, 1303-1315 (2010).
54. S. Mitra, C. Beach, G. S. Feng, R. Plattner, SHP-2 is a novel target of Abl kinases during cell proliferation. J. Cell Sci. 121, 3335-3346 (2008).
55. J. F. Cloutier, L. M. Chow, A. Veillette, Requirement of the SH3 and SH2 domains for the inhibitory function of tyrosine protein kinase p50csk in T lymphocytes. Mol. Cell. Biol. 15, 5937-5944 (1995).
56. D. Davidson, J. F. Cloutier, A. Gregorieff, A. Veillette, Inhibitory tyrosine protein kinase p50csk is associated with protein-tyrosine phosphatase PTP-PEST in hemopoietic and non-hemopoietic cells. J. Biol. Chem. 272, 23455-23462 (1997).
57. Y. P. Chong, T. D. Mulhern, H. J. Zhu, D. J. Fujita, J. D. Bjorge, J. P. Tantiongco, N. Sotirellis, D. S. S. Lio, G. Scholz, H. C. Cheng, A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity. J. Biol. Chem. 279, 20752-20766 (2004).
58. B. B. Au-Yeung, S. E. Levin, C. Zhang, L. Y. Hsu, D. A. Cheng, N. Killeen, K. M. Shokat, A. Weiss, A genetically selective inhibitor demonstrates a function for the kinase Zap70 in regulatory T cells independent of its catalytic activity. Nat. Immunol. 11, 1085-1092 (2010).
59. G. Sun, A. K. Sharma, R. J. Budde, Autophosphorylation of Src and Yes blocks their inactivation by Csk phosphorylation. Oncogene 17, 1587-1595 (1998).
60. S. Gonfloni, A. Weijland, J. Kretzschmar, G. Superti-Furga, Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat. Struct. Biol. 7, 281-286 (2000).
61. J. Wu, F. Meng, L. Y. Kong, Z. Peng, Y. Ying, W. G. Bornmann, B. G. Darnay, B. Lamothe, H. Sun, M. Talpaz, N. J. Donato, Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J. Natl. Cancer Inst. 100, 926-939 (2008).
62. c-src can induce focus formation without complete transformation of NIH 3T3 cells. Mol. Cell. Biol. 5, 1073-1083 (1985).
63. J. Dengjel, V. Akimov, J. V. Olsen, J. Bunkenborg, M. Mann, B. Blagoev, J. S. Andersen, Quantitative proteomic assessment of very early cellular signaling events. Nat. Biotechnol. 25, 566-568 (2007).
64. C. Ritz, J. C. Streibig, Bioassay analysis using R. J. Stat. Softw. 12, 1-22 (2005).
65. J. E. Elias, W. Haas, B. K. Faherty, S. P. Gygi, Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat. Methods 2, 667-675 (2005).
66. S. A. Beausoleil, J. Villen, S. A. Gerber, J. Rush, S. P. Gygi, A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat. Biotechnol. 24, 1285-1292 (2006).
67. A. Prakash, P. Mallick, J. Whiteaker, H. Zhang, A. Paulovich, M. Flory, H. Lee, R. Aebersold, B. Schwikowski, Signal maps for mass spectrometry-based comparative proteomics. Mol. Cell. Proteomics 5, 423-432 (2006).
68. M. B. Eisen, P. T. Spellman, P. O. Brown, D. Botstein, Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95, 14863-14868 (1998).
69. S. E. Ong, M. Mann, A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat. Protoc. 1, 2650-2660 (2006).
70. R. Amanchy, D. E. Kalume, A. Pandey, Stable isotope labeling with amino acids in cell culture (SILAC) for studying dynamics of protein abundance and posttranslational modifications. Sci. STKE 2005, pl2 (2005).
71. A. J. Link, J. Labaer, In-gel trypsin digest of gel-fractionated proteins. Cold Spring Harb. Protoc. 2009, pdb.prot5110 (2009).
72. G. E. Crooks, G. Hon, J. M. Chandonia, S. E. Brenner, WebLogo: A sequence logo generator. Genome Res. 14, 1188-1190 (2004).
73. R. A. Fisher, Statistical Methods for Research Workers (Oliver and Boyd, Edinburgh, 1925).
74. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 57, 289-300 (1995).
75. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).
76. Acknowledgments: We thank H. Herschman [University of California-Los Angeles (UCLA)] for generously providing the pMvsrc plasmid, C. Sawyers (Memorial Sloan-Kettering Cancer Center) for the pMSCVpuro-p210 plasmid, and N. Graham for critical reading of the manuscript. Funding: B.T. is a postdoctoral fellow of the German Academic Exchange Service, and S.S.C. is a recipient of the UCLA Tumor Biology Program U.S. Department of Health and Human Services Ruth L. Kirschstein Institutional National Research Service Award # T32 CA009056. M.M. is a scholar of the Leukemia and Lymphoma Society (LLS1497-11) and is supported by NIH grants R01CA137060 and R01CA139032. T.G.G. is an Alfred P. Sloan Research Fellow. Funding for the research was provided by grants to T.G.G. from the NIH NHGRI (HG002807) and the University of California Cancer Research Coordinating Committee. Author contributions: L.R., B.T., L.B., E.G., T.L., and M.T. performed the experiments. B.T., E.K., and S.S.C. performed MS analysis. L.R., B.T., E.K., M.P., and T.G.G. performed the data and bioinformatic analyses. B.S. and M.M. provided reagents and interpreted the data. L.R. and T.G.G. wrote the manuscript. Competing interests: The authors declare that they have no competing interests. Data availability: The MS data associated with this manuscript may be downloaded from http://systems.crump.ucla.edu/data/.